IU
IUGNF.US Imugene Limited
- Market cap
- USD 16.1M
- P/E
- -
- P/B
- 2.61x
- ROE
- -1,169.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is IUGNF.US undervalued?
Graham numberThe Graham number of Imugene Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Imugene Limited fundamental analysis
No fundamental analysis for Imugene Limited yet.
Imugene Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Imugene Limited
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to gener…
Full company profileImugene Limited financial statements
Imugene Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.16M | 1.84M | 4.13M | 4.13M | 7.23M | 13.0M | 11.8M | 4.97M | 4.40M | - |
| Gross Profit | 1.16M | 1.84M | 4.06M | 4.05M | 5.27M | 10.6M | 9.57M | 4.97M | 4.40M | -6.83M |
| Operating Income | -3.69M | -5.78M | -12.4M | -10.8M | -18.5M | -37.9M | -39.8M | -154M | -70.9M | -74.8M |
| EBITDA | -3.67M | -5.77M | -7.71M | -14.6M | -23.8M | -35.4M | -47.5M | -148M | -66.5M | -68.0M |
| Net Income | -2.51M | -3.93M | -7.78M | -10.5M | -18.5M | -37.9M | -37.9M | -150M | -69.0M | -105M |
| EPS | -0.04 | -0.05 | -0.07 | -0.09 | -0.13 | -0.23 | -0.21 | -0.72 | -0.32 | -0.32 |
| Balance Sheet | ||||||||||
| Total Assets | 12.7M | 16.9M | 30.8M | 65.2M | 71.8M | 148M | 197M | 151M | 83.6M | 23.0M |
| Total Liabilities | 1.28M | 1.44M | 3.48M | 5.40M | 6.79M | 8.90M | 7.44M | 33.1M | 38.6M | 14.0M |
| Shareholders' Equity | 11.4M | 15.5M | 27.3M | 59.8M | 65.0M | 139M | 190M | 118M | 45.0M | 9.00M |
| Cash & Short-term Investments | 4.81M | 7.82M | 19.0M | 30.1M | 29.5M | 99.9M | 153M | 94.5M | 21.9M | 2.63M |
| Total Debt | - | - | 123K | 69.3K | 271K | 673K | 553K | 1.55M | 10.7M | 6.29M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -2.67M | -4.51M | -7.91M | -10.1M | -13.1M | -30.7M | -29.8M | -102M | -75.6M | -44.8M |
| Capital Expenditure | 2.03K | 3.33K | 128K | 1.49M | 5.45M | 258K | 0.00 | 7.07M | 14.5M | 4.33 |
| Free Cash Flow | -2.68M | -4.51M | -8.04M | -11.6M | -18.6M | -30.9M | -29.8M | -109M | -90.0M | -44.8M |
| Ratios | ||||||||||
| ROE | -22.0% | -25.4% | -28.5% | -17.6% | -28.4% | -27.3% | -20.0% | -126.6% | -153.3% | -1,169.2% |
| ROA | -19.8% | -23.3% | -25.3% | -16.1% | -25.7% | -25.7% | -19.2% | -98.9% | -82.6% | -457.4% |
| Net Profit Margin | -215.4% | -213.7% | -188.4% | -254.2% | -255.2% | -292.0% | -321.9% | -3,011.7% | -1,569.8% | - |
| Debt to Equity | - | - | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.01x | 0.24x | 0.70x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Imugene Limited dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 134K | 0.00 | - |
| 2021 | USD 144K | 0.00 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:34 on Jul 2, 2025.
Who owns Imugene Limited
- Insiders 9.94%
- Institutions 9.22%
- Public & others 80.84%
- Shares outstanding 554M
- Free float 438M
Imugene Limited company profile
- Company name
- Imugene Limited
- Ticker
- IUGNF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Fiscal year end
- June
- Address
- 4-6 Bligh Street, Sydney, NSW, Australia, 2000
- Phone
- 61 2 9423 0881
- Website
- imugene.com
About Imugene Limited
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and Neo-POLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.
Imugene Limited management
4- Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICDExecutive Chairman · born 1956
- Mr. Darren Michael Keamy B.Com., CPACFO & Company Secretary · born 1973
- Ms. Ursula McCurryChief Clinical Operations Officer
- Dr. John Le Gall M.B.A., M.D.Chief Medical Officer